Factors related to the improvement in quality of life for depressed inpatients treated with fluoxetine

Wei-Cheng Yang, Ching-Hua Lin, Fu-Chiang Wang, Mei-Jou Lu, Wei-Cheng Yang, Ching-Hua Lin, Fu-Chiang Wang, Mei-Jou Lu

Abstract

Background: The aim of this study was to explore the relationships between depressive symptoms and health-related quality of life (HRQOL) measurements for inpatients with major depressive disorder (MDD) before and after 6-week fluoxetine treatment, and to elucidate the factors related to the HRQOL changes.

Methods: A total of 131 inpatients with MDD were enrolled to receive 20 mg of fluoxetine for 6 weeks. Symptom severity and adverse events were assessed at weeks 0, 1, 2, 3, 4, and 6 using the 17-item Hamilton Depression Rating Scale (HAMD-17) and UKU Side Effect Rating Scale, respectively. HRQOL was measured using the Short Form 36 (SF-36), including 8 subscales, physical component summary (PCS) and mental component summary (MCS), at baseline and week 6. Spearman's coefficient, Cohen's d, and multiple linear regression model were used for statistical analysis.

Results: One hundred and six patients completing all measures at weeks 0 and 6 entered the analysis. HAMD-17 negatively correlated with SF-36 at baseline and week 6. The HAMD-17 had a larger effect size than SF-36. MCS, rather than PCS, showed statistically significant improvement. After using multiple linear regression analysis, age at onset, HAMD-17 score change, and number of adverse events reported during the trial period were related to MCS change after adjusting for confounding variables.

Conclusions: Fluoxetine treatment was associated with an improvement in depressive symptomology and HRQOL. Depressive symptoms had a greater extent of change than HRQOL. Clinicians must consider the negative effects of adverse events caused by antidepressants on the improvement of HRQOL.

Trial registration: https://ichgcp.net/clinical-trials-registry/NCT01075529" title="See in ClinicalTrials.gov">NCT01075529 , retrospectively registered 24/2/2010.

Conflict of interest statement

Ethics approval and consent to participate

The trial was approved by Kai-Syuan Psychiatric Hospital’s institutional review board. Written, informed consent was obtained from all participants.

Consent to publication

Not applicable.

Competing interests

The authors declare no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Selection of participants for the analysis

References

    1. Ebrahim S. Clinical and public health perspectives and applications of health-related quality of life measurement. Soc Sci Med. 1995;41(10):1383–1394. doi: 10.1016/0277-9536(95)00116-O.
    1. Mendlowicz MV, Stein MB. Quality of life in individuals with anxiety disorders. Am J Psychiatry. 2000;157(5):669–682. doi: 10.1176/appi.ajp.157.5.669.
    1. Patrick DL, Erickson P. What constitutes quality of life? Concepts and dimensions. Clin Nutr. 1988;7:53–63.
    1. Patten SB, Kennedy SH, Lam RW, O'Donovan C, Filteau MJ, Parikh SV, Ravindran AV. Canadian Network for M, Anxiety T: Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management. Journal of affective disorders. 2009;117(Suppl 1):S5–14. doi: 10.1016/j.jad.2009.06.044.
    1. ten Doesschate MC, Koeter MW, Bockting CL, Schene AH, Group DS Health related quality of life in recurrent depression: a comparison with a general population sample. J Affect Disord. 2010;120(1–3):126–132. doi: 10.1016/j.jad.2009.04.026.
    1. Katschnig H, Freeman HL, Sartorius N. Quality of life in mental disorders, 2nd ed. Edn. Chichester: Wiley; 2006.
    1. De Fruyt J, Demyttenaere K. Quality of life measurement in antidepressant trials. Is there an added value? Psychother Psychosom. 2009;78(4):212–219. doi: 10.1159/000214442.
    1. Rapaport MH, Clary C, Fayyad R, Endicott J. Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry. 2005;162(6):1171–1178. doi: 10.1176/appi.ajp.162.6.1171.
    1. Wisniewski SR, Rush AJ, Bryan C, Shelton R, Trivedi MH, Marcus S, Husain MM, Hollon SD, Fava M, Investigators SD. Comparison of quality of life measures in a depressed population. J Nerv Ment Dis. 2007;195(3):219–225. doi: 10.1097/01.nmd.0000258229.38212.6f.
    1. Souetre E, Martin P, Lozet H, Monteban H. Quality of life in depressed patients: comparison of fluoxetine and major tricyclic antidepressants. Int Clin Psychopharmacol. 1996;11(1):45–52. doi: 10.1097/00004850-199603000-00006.
    1. Gelenberg AJ, Freeman MP, Markowitz JC, Rosenbaum JF, Thase ME, Trivedi MH, Van Rhoads RS, Reus VI, Raymond DePaulo Jr M J, Fawcett JA Practice guideline for the treatment of patients with major depressive disorder third edition. Am J Psychiatry. 2010;167(10):1–152.
    1. Lin CH, Lane HY, Chen CC, Juo SH, Yen CF. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J Clin Psychopharmacol. 2011;31(2):187–193. doi: 10.1097/JCP.0b013e318210856f.
    1. APA: American Psychiatric Association: Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiatric Press; 1994.
    1. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62. doi: 10.1136/jnnp.23.1.56.
    1. Guy W: ECDEU Assessment manual for psychopharmacology. Washington DC: DHEW Publication 76338; 1976.
    1. Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol. 1999;9(1–2):83–91. doi: 10.1016/S0924-977X(98)00004-2.
    1. Schatzberg AF, Nemeroff CB. Essentials of clinical psychopharmacology. Washington, DC: American Psychiatric Pub; 2001.
    1. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K The UKU side effect rating scale A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334:1–100. doi: 10.1111/j.1600-0447.1987.tb10566.x.
    1. Pjrek E, Konstantinidis A, Assem-Hilger E, Praschak-Rieder N, Willeit M, Kasper S, Winkler D. Therapeutic effects of escitalopram and reboxetine in seasonal affective disorder: a pooled analysis. J Psychiatr Res. 2009;43(8):792–797. doi: 10.1016/j.jpsychires.2008.11.004.
    1. Harrison CL, Ferrier N, Young AH. Tolerability of high-dose venlafaxine in depressed patients. J Psychopharmacol. 2004;18(2):200–204. doi: 10.1177/0269881104042621.
    1. Daly EJ, Trivedi MH, Fava M, Shelton R, Wisniewski SR, Morris DW, Stegman D, Preskorn SH, Rush AJ. The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study. J Clin Psychopharmacol. 2011;31(1):31–38. doi: 10.1097/JCP.0b013e318205e17b.
    1. Ware JE, Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–483. doi: 10.1097/00005650-199206000-00002.
    1. Ware J.E. KM, Keller S.D. : SF-36 physical and mental health summary scales: a User's manual. Boston,MA: The Health Institute; 1994.
    1. Ware JE, Kosinski M. Interpreting SF-36 summary health measures: a response. Qual Life Res. 2001;10(5):405–413. doi: 10.1023/A:1012588218728.
    1. Tseng HM, Lu JF, Tsai YJ. Assessment of health-relate quality of life: II. Norming and validation of SF-36 Taiwan version. Taiwan Journal of Public Helth. 2003;22(2):512–518.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2. Hillsdale, NJ: Lawrence Erlbaum; 1988.
    1. Morris SB, DeShon RP. Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods. 2002;7(1):105–125. doi: 10.1037/1082-989X.7.1.105.
    1. Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter WZ. The responsiveness of the Hamilton depression rating scale. J Psychiatr Res. 2000;34(1):3–10. doi: 10.1016/S0022-3956(99)00037-0.
    1. Forthofer RN, Lee ES, Hernandez M. Biostatistics : a guide to design, analysis, and discovery, 2nd ed. Edn. Amsterdam. London: Elsevier Academic Press; 2007.
    1. IsHak WW, Greenberg JM, Balayan K, Kapitanski N, Jeffrey J, Fathy H, Fakhry H, Rapaport MH. Quality of life: the ultimate outcome measure of interventions in major depressive disorder. Harv Rev Psychiatry. 2011;19(5):229–239. doi: 10.3109/10673229.2011.614099.
    1. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care - a randomized trial. Jama-Journal of the American Medical Association. 2001;286(23):2947–2955. doi: 10.1001/jama.286.23.2947.
    1. Mann R, Gilbody S, Richards D. Putting the 'Q' in depression QALYs: a comparison of utility measurement using EQ-5D and SF-6D health related quality of life measures. Soc Psychiatry Psychiatr Epidemiol. 2009;44(7):569–578. doi: 10.1007/s00127-008-0463-5.
    1. Enns MW, Larsen DK, Cox BJ. Discrepancies between self and observer ratings of depression. The relationship to demographic, clinical and personality variables. J Affect Disord. 2000;60(1):33–41. doi: 10.1016/S0165-0327(99)00156-1.
    1. Moller HJ. Rating depressed patients: observer- vs self-assessment. Eur Psychiatry. 2000;15(3):160–172. doi: 10.1016/S0924-9338(00)00229-7.
    1. Dunlop BW, Li T, Kornstein SG, Friedman ES, Rothschild AJ, Pedersen R, Ninan P, Keller M. Correlation between patient and clinician assessments of depression severity in the PREVENT study. Psychiatry Res. 2010;177(1–2):177–183. doi: 10.1016/j.psychres.2010.02.008.
    1. Moller HJ, von Zerssen D. Self-rating procedures in the evaluation of antidepressants. Psychopathology. 1995;28(6):291–306. doi: 10.1159/000284941.
    1. Giesecke T, Gracely RH, Williams DA, Geisser ME, Petzke FW, Clauw DJ. The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis Rheum. 2005;52(5):1577–1584. doi: 10.1002/art.21008.
    1. Hotopf M, Mayou R, Wadsworth M, Wessely S. Temporal relationships between physical symptoms and psychiatric disorder. Results from a national birth cohort. The British journal of psychiatry : the journal of mental science. 1998;173:255–261. doi: 10.1192/bjp.173.3.255.
    1. Von Korff M, Simon G. The relationship between pain and depression. Br J Psychiatry Suppl. 1996;30:101–108.
    1. Gureje O. Psychiatric aspects of pain. Curr Opin Psychiatry. 2007;20(1):42–46. doi: 10.1097/YCO.0b013e328010ddf4.
    1. Hung CI, Wang SJ, Liu CY. Validation of the depression and somatic symptoms scale by comparison with the short form 36 scale among psychiatric outpatients with major depressive disorder. Depress Anxiety. 2009;26(6):583–591. doi: 10.1002/da.20464.
    1. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, Stang P, Zhou XH, Hays R, Weinberger M. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286(23):2947–2955. doi: 10.1001/jama.286.23.2947.
    1. Bech P, Tanghoj P, Cialdella P, Andersen HF, Pedersen AG. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum. 2004;7(3):283–290. doi: 10.1017/S1461145704004365.
    1. Cao Y, Li W, Shen J, Malison RT, Zhang Y, Luo X. Health-related quality of life and symptom severity in Chinese patients with major depressive disorder. Asia Pac Psychiatry. 2013;5(4):276–283. doi: 10.1111/appy.12059.
    1. Kohler S, Unger T, Hoffmann S, Mackert A, Ross B, Fydrich T. The relationship of health-related quality of life and treatment outcome during inpatient treatment of depression. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2015;24(3):641–649. doi: 10.1007/s11136-014-0811-8.
    1. Howard KI, Lueger RJ, Maling MS, Martinovich Z. A phase model of psychotherapy outcome: causal mediation of change. J Consult Clin Psychol. 1993;61(4):678–685. doi: 10.1037/0022-006X.61.4.678.
    1. McCall WV, Rosenquist PB, Kimball J, Haskett R, Isenberg K, Prudic J, Lasater B, Sackeim HA. Health-related quality of life in a clinical trial of ECT followed by continuation pharmacotherapy: effects immediately after ECT and at 24 weeks. The journal of ECT. 2011;27(2):97–102. doi: 10.1097/YCT.0b013e318205c7d7.
    1. Papakostas GI, Petersen T, Mahal Y, Mischoulon D, Nierenberg AA, Fava M. Quality of life assessments in major depressive disorder: a review of the literature. Gen Hosp Psychiatry. 2004;26(1):13–17. doi: 10.1016/j.genhosppsych.2003.07.004.
    1. Reed C, Monz BU, Perahia DGS, Gandhi P, Bauer M, Dantchev N, Demyttenaere K, Garcia-Cebrian A, Grassi L, Quail D, et al. Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER. J Affect Disord. 2009;113(3):296–302. doi: 10.1016/j.jad.2008.05.021.
    1. Diehr PH, Derleth AM, McKenna SP, Martin ML, Bushnell DM, Simon G, Patrick DL. Synchrony of change in depressive symptoms, health status, and quality of life in persons with clinical depression. Health Qual Life Outcomes. 2006;4:27. doi: 10.1186/1477-7525-4-27.
    1. McHorney CA, Ware JE, Jr, Raczek AE. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–263. doi: 10.1097/00005650-199303000-00006.
    1. Moses T, Leuchter AF, Cook I, Abrams M. Does the clinical course of depression determine improvement in symptoms and quality of life? J Nerv Ment Dis. 2006;194(4):241–248. doi: 10.1097/01.nmd.0000207358.15230.80.
    1. Kaufman J, Martin A, King RA, Charney D. Are child-, adolescent-, and adult-onset depression one and the same disorder? Biol Psychiatry. 2001;49(12):980–1001. doi: 10.1016/S0006-3223(01)01127-1.
    1. Zisook S, Lesser I, Stewart JW, Wisniewski SR, Balasubramani GK, Fava M, Gilmer WS, Dresselhaus TR, Thase ME, Nierenberg AA, et al. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry. 2007;164(10):1539–1546. doi: 10.1176/appi.ajp.2007.06101757.
    1. Klein DN, Schatzberg AF, McCullough JP, Dowling F, Goodman D, Howland RH, Markowitz JC, Smith C, Thase ME, Rush AJ, et al. Age of onset in chronic major depression: relation to demographic and clinical variables, family history, and treatment response. J Affect Disord. 1999;55(2–3):149–157. doi: 10.1016/S0165-0327(99)00020-8.
    1. Miller IW, Keitner GI, Schatzberg AF, Klein DN, Thase ME, Rush AJ, Markowitz JC, Schlager DS, Kornstein SG, Davis SM, et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. The Journal of clinical psychiatry. 1998;59(11):608–619. doi: 10.4088/JCP.v59n1108.
    1. Fava M, Mallinckrodt CH, Detke MJ, Watkin JG, Wohlreich MM. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? The Journal of clinical psychiatry. 2004;65(4):521–530. doi: 10.4088/JCP.v65n0411.
    1. Berlim MT, McGirr A, Fleck MP. Can sociodemographic and clinical variables predict the quality of life of outpatients with major depression? Psychiatry Res. 2008;160(3):364–371. doi: 10.1016/j.psychres.2007.07.024.
    1. Barge-Schaapveld DQ, Nicolson NA. Effects of antidepressant treatment on the quality of daily life: an experience sampling study. The Journal of clinical psychiatry. 2002;63(6):477–485. doi: 10.4088/JCP.v63n0603.
    1. Cheung AH, Levitt AJ, Szalai JP. Impact of antidepressant side effects on adolescent quality of life. Can J Psychiatry. 2003;48(11):727–733. doi: 10.1177/070674370304801104.
    1. Beasley CM, Jr, Nilsson ME, Koke SC, Gonzales JS. Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. The Journal of clinical psychiatry. 2000;61(10):722–728. doi: 10.4088/JCP.v61n1003.
    1. Uzun S, Kozumplik O. Management of side effects of antidepressants - brief review of recommendations from guidelines for treatment of major depressive disorder. Psychiatr Danub. 2009;21(1):91–94.
    1. Walsh BT, Seidman SN, Sysko R, Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA. 2002;287(14):1840–1847. doi: 10.1001/jama.287.14.1840.
    1. Khan A, Leventhal RM, Khan SR, Brown WA. Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol. 2002;22(1):40–45. doi: 10.1097/00004714-200202000-00007.
    1. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2) doi: 10.1371/journal.pmed.0050045.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi